• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

    5/15/25 4:15:23 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Elevation Oncology, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    28623U101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    TANG CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,043,921.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,043,921.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,043,921.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Tang Capital Management, LLC ("TCM") beneficially owns 6,043,921 shares of the Issuer's Common Stock, which consists of: (i) 4,760,000 shares of the Issuer's Common Stock and (ii) 1,283,921 shares currently issuable upon exercise of Warrants (the "Warrants," as defined in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on June 9, 2023). The percentages used herein are based on 60,499,716 shares of Common Stock outstanding, which is comprised of: (i) 59,215,795 shares of Common Stock outstanding as of February 28, 2025, as set forth in the Issuer's Annual Report filed on Form 10-K that was filed with the Securities and Exchange Commission on March 6, 2025 and (ii) 1,283,921 shares currently issuable upon exercise of Warrants. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc ("TCP III") and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    KEVIN TANG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,043,921.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,043,921.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,043,921.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Kevin Tang beneficially owns 6,043,921 shares of the Issuer's Common Stock, which consists of: (i) 4,760,000 shares of the Issuer's Common Stock and (ii) 1,283,921 shares currently issuable upon exercise of Warrants. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III and TCM.


    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,052,545.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,052,545.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,052,545.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.35 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  TCP beneficially owns 5,052,545 shares of the Issuer's Common Stock, which is comprised of: (i) 3,768,624 shares of Common Stock and (ii) 1,283,921 shares currently issuable upon exercise of Warrants. TCP owns 3,750,000 of the Issuer's Warrants, which are each exercisable for one share of the Issuer's Common Stock. The Warrants are immediately exercisable and expire five years from the date of issuance. TCP may not exercise any portion of the Warrants for shares of Common Stock if, as a result of the exercise, TCP, together with its affiliates and any other person or entity acting as a group, would own more than 9.99% of the Issuer's outstanding shares of Common Stock after exercise. The foregoing limitations remain in effect with respect to the Warrants, and, accordingly, only 1,283,921 shares are currently issuable upon exercise of the Warrants. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS INTERNATIONAL, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    551,376.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    551,376.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    551,376.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.91 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS III, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    440,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    440,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    440,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.73 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    28623U101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS IV, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Elevation Oncology, Inc.
    (b)Address of issuer's principal executive offices:

    101 Federal Street, Suite 1900, Boston, MA, 02110
    Item 2. 
    (a)Name of person filing:

    This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of TCP III and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.
    (b)Address or principal business office or, if none, residence:

    The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
    (c)Citizenship:

    TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    28623U101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6,043,921
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0 shares

     (ii) Shared power to vote or to direct the vote:

    6,043,921 shares

     (iii) Sole power to dispose or to direct the disposition of:

    0 shares

     (iv) Shared power to dispose or to direct the disposition of:

    6,043,921 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TANG CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager
    Date:05/15/2025
     
    KEVIN TANG
     
    Signature:/s/ Kevin Tang
    Name/Title:Self
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS INTERNATIONAL, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS III, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS IV, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:05/15/2025
    Get the next $ELEV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

      -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

      5/15/25 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

      4/25/25 1:00:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

      -- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- -- On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON, March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the Amer

      3/25/25 4:30:00 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    See more
    • Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

      BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

      3/4/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

      BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

      1/22/24 7:30:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

      NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

      7/13/23 8:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Furlong Tammy converted options into 2,643 shares and covered exercise/tax liability with 784 shares, increasing direct ownership by 23% to 10,075 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:15:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 6,250 shares and covered exercise/tax liability with 2,303 shares, increasing direct ownership by 3% to 137,152 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      5/19/25 4:10:05 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF EXECUTIVE OFFICER Ferra Joseph J Jr converted options into 12,562 shares and covered exercise/tax liability with 4,628 shares, increasing direct ownership by 6% to 133,205 units (SEC Form 4)

      4 - Elevation Oncology, Inc. (0001783032) (Issuer)

      3/18/25 4:15:13 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:50:19 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 7:05:59 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

      SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      11/14/24 6:45:37 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:27:14 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elevation Oncology Inc.

      SCHEDULE 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

      5/15/25 4:15:23 PM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Elevation Oncology, Inc. (0001783032) (Filer)

      5/15/25 7:45:11 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Elevation Oncology downgraded by Stephens with a new price target

      Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

      3/24/25 8:34:27 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

      3/21/25 8:03:34 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology downgraded by Citizens JMP

      Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

      3/21/25 8:03:24 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELEV
    Financials

    Live finance-specific insights

    See more
    • Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

      -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

      8/6/24 7:10:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

      -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

      8/6/24 7:00:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

      Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

      7/28/22 8:45:00 AM ET
      $ELEV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care